HOME >> BIOLOGY >> NEWS
Moffitt Cancer Center receives DoD funds to establish National Functional Genomics Project

The H. Lee Moffitt Cancer Center & Research Institute has been awarded $3.2 million by the United States Department of Defense to establish the National Functional Genomics Project (NFGP), an innovative partnership between academia, government, and industry. The goal of the NFGP is to develop new technologies in molecular medicine to advance the early detection, diagnosis, and treatment of cancer and other chronic diseases.

"Functional genomics is the hottest topic in cancer research today," says William Dalton, PhD, MD, Moffitt's new CEO and Center Director. "It could completely change the practice of medicine within five years."

The resolution of the human genome into separate genes provided the blueprint for understanding disease processes. However, unraveling the functional significance of these genes is central to solving the problems posed by cancer and other diseases. "Each cancer is unique" explains Jack Pledger, PhD, Moffitt's Deputy Director and head of basic research, who will also serve as Scientific Director of the NFGP. "We need to pay attention to the molecular changes that give rise to cancer, rather than just looking at where the cancer started out. Molecular diagnosis may be better than a diagnosis based on just what the tumor looks like--or whether it started out in the lung, prostate, or breast."

The primary function of the NFGP will be to track the genetic changes involved in cancer, allowing the design of more effective therapeutic agents and a better understanding of the hereditary and environmental influences that contribute to cancer and other diseases. "We need a new way to classify tumors," says Pledger. "The current method of categorizing them based solely on the tissue they arise in is not adequate for relating how they respond to chemotherapy."

The NFGP will be an integrated research program focusing on gene expression analysis, genetics, proteomics, and translational research, with a bioinformat
'"/>

Contact: Andrea Lazarus
lazarual@moffitt.usf.edu
813-632-1396
Moffitt Cancer Center and Research Institute
12-Sep-2002


Page: 1 2

Related biology news :

1. Moffitt teams with DNAPrint(TM) to predict patient response to chemotherapy
2. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
3. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
4. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Cancer gene MYC emerging as key research target
6. Cancer patient, heal thyself
7. USC researcher named General Motors Cancer Research Scholar
8. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
9. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
10. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
11. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection ... Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced its newly ... health agencies of all sizes. With a focus on tracking symptoms and monitoring ... health care, Mosio helps public health departments automate communications and provide more personalized ...
(Date:8/7/2020)... ... August 06, 2020 , ... ... in the prestigious National STEM Scholar Program, a unique professional development program that ... project support for middle school science teachers nationwide. , Created in partnership between ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a leading ... food industries, is pleased to announce that Charles Galea has joined its clinical ... Charles is an accomplished and results-driven sales executive with over 10 years of ...
(Date:7/10/2020)... , ... July 09, 2020 , ... ... cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as ... oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... today announced the company has entered a license agreement with Roswell Park Comprehensive ... globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device ...
Breaking Biology Technology:
Cached News: